Novadaq Technologies Inc.
TSX : NDQ

Novadaq Technologies Inc.

May 01, 2007 07:00 ET

Novadaq Announces First Quarter 2007 Conference Call and Webcast and Annual Meeting

TORONTO, ONTARIO--(Marketwire - May 1, 2007) -

Attention Business/Financial Editors:

Novadaq® Technologies Inc. (TSX:NDQ), a developer of real-time medical
imaging systems and image guided therapies for the operating room, will host
a conference call and live webcast to discuss the financial results for the
first quarter ended March 31, 2007. The Company will also host its annual
meeting on Tuesday, May 15 to discuss fiscal 2006. Both meetings will be
hosted by Dr. Arun Menawat, President and Chief Executive Officer, and Mr.
Roger Deck, Chief Financial Officer.



QUARTERLY CONFERENCE CALL

Date: May 7, 2007

Time: 4:30 pm, Eastern Time

Dial in number: 416-644-3425 or 1-800-591-7539

Taped replay: 416-640-1917 or 1-877-289-8525
(Available until May 14th, 2007)

Code number: 21231178

Webcast: A live audio webcast of the call will be available at
www.novadaq.com.

Webcast attendees are welcome to listen to the conference
in real-time or on-demand at your convenience. The
webcast will be archived for 90 days. Please connect to
this website at least 15 minutes prior to the conference
call to ensure adequate time for any software download
that may be needed to hear the webcast.

ANNUAL MEETING

Date: May 15, 2007

Time: 10:30 am, Eastern Time

Location: The National Club, Howland Room
303 Bay St.
Toronto, Ontario, Canada

Webcast: A live audio webcast of the call will be available at
www.novadaq.com.

Webcast attendees are welcome to listen to the conference
in real-time or on-demand at your convenience. The
webcast will be archived for 90 days. Please connect to
this website at least 15 minutes prior to the conference
call to ensure adequate time for any software download
that may be needed to hear the webcast.


About Novadaq Technologies

Novadaq Technologies Inc. (TSX:NDQ) develops and commercializes medical
imaging systems and real-time image guided therapies for use in the operating
room. Novadaq's proprietary imaging platform can be used to visualize blood
vessels, nerves and the lymphatic system during surgical procedures. Novadaq's
SPY® Imaging System, commercially available worldwide, enables cardiac
surgeons to visually assess coronary vasculature and bypass graft
functionality during the course of open-heart surgery. Novadaq's OPTTX®
System which received CE Mark approval in November 2006, is aimed at the
diagnosis, evaluation and treatment of wet Age-related Macular Degeneration
(AMD) by using the same core imaging technology that is used in the SPY
System. The HELIOS™ Imaging System, which received FDA clearance in January
2007, is the first fluorescent imaging system available for use during plastic
reconstructive surgery allowing surgeons to evaluate pre- and intra-operative
blood flow, as well as post-surgery perfusion. Novadaq's LUNA™ Imaging
System is designed to enable surgeons to visualize nerve bundles during the
course of urological and neurological procedures. LUNA™ has been granted a
license for use by Health Canada. Novadaq is also the exclusive United States
distributor of PLC Medical's CO(2) HEART LASER™ System for TMR
(Trans-Myocardial Revascularization). For more information, please visit the
company's website at www.novadaq.com.

Forward-looking Statements

Certain statements included in this press release may be considered
forward-looking. Such statements involve known and unknown risks,
uncertainties and other factors that may cause actual results, performance or
achievements to be materially different from those implied by such statements,
and therefore these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based on Novadaq's
current beliefs as well as assumptions made by and information currently
available to Novadaq and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory developments, market
acceptance and future commitments, including (among other matters) that
Novadaq will complete its proposed private placement on the basis described
herein or at all. Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this press
release. Due to risks and uncertainties, including the risks and uncertainties
identified by Novadaq in its public securities filings; actual events may
differ materially from current expectations. Novadaq disclaims any intention
or obligation to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.

For further information: visit our website at www.novadaq.com.

Contact Information